Igenomix Canada

The Vitrolife Group was pleased to sponsor the CFAS/ASRM Business in Medicine Summit in Banff, Alberta. Blair and Alissa had a great time catching up with friends and colleagues, old and new!

Wha

ERA works when applied in the indicated population (RIF) and when adhering to proper protocol compliance.
When ERA is used correctly, you can maximize the chances of embryo implantation and further optimize patient outcomes.

💻 Today we want to share a useful clinical tool that can be used both in office and with patients. The ERA Checklist helps organize ERA mock and personalized embryo transfer (pET) cycles, ensuring proper protocol compliance and reproducibility, with the aim to further improve clinical outcomes. 🤰

👉 Link here to visit the complete ERA hub: ERA works worldwide - https://ow.ly/QGz150SbtUA
👉 Link here to download the ERA Checklist: https://ow.ly/1KVV50SbtUy

📢📢 Exciting news! It is a pleasure to share with you a new digital hub where you can access helpful information and clinical tools pertaining to our ERA test.

As you well know, ERA works when applied in the indicated population (RIF) and when adhering to proper protocol compliance. When ERA is used correctly, you can maximize the chances of embryo implantation and further optimize patient outcomes.

💻 This new digital tool features:

✔️Physician-user testimonials from around the world
✔️Tips from our scientific community
✔️Clinic ERA tools
✔️Webinars that focus on protocol compliance
And much more!

We will continue to update the ERA digital hub with new content to support you, so together we can help your patients achieve their goal of a healthy pregnancy. 🤰

Visit our new ERA hub: https://www.igenomix.eu/era-works-worldwide/

ERA works when applied in the indicated population (RIF) and when adhering to proper protocol compliance.

When ERA is used correctly, you can maximize the chances of embryo implantation and further optimize patient outcomes.

💻 Today we want to share a useful clinical tool that can be used both in office and with patients. The ERA Checklist helps organize ERA mock and personalized embryo transfer (pET) cycles, ensuring proper protocol compliance and reproducibility, with the aim to further improve clinical outcomes. 🤰

Link here to visit the complete ERA hub: ERA works worldwide - https://www.igenomix.eu/era-works-worldwide/

Link here to download the ERA Checklist:https://www.igenomix.eu/wp-content/uploads/sites/25/2024/05/ERA-Checklist.pdf

🔬 Exciting News Alert! Join us for our upcoming webinar hosted by Igenomix! 🔬

📅 Date: May 16th
🕒 Time: 11am PST / 2pm EST
🔗 Registration Link: https://register.gotowebinar.com/register/726602802566427740?utm_source=Marketing_Cloud&utm_medium=email&utm_campaign=USA+-+CGT+Webinar+-+Closing+the+Gap+on+Carrier+Screening+by+Igenomix&utm_term=CLICK+HERE&utm_id=1094878&sfmc_id=438174598

Empowering informed decisions in genetic health is at the core of what we do at Igenomix. That's why we're thrilled to extend an exclusive invitation to you for our upcoming webinar, "Closing the Gaps in Carrier Screening."

Carrier Genetic Testing (CGT) is revolutionizing genetic screening, offering unparalleled insights into potential risks that could affect future generations. Join us as we explore how CGT, powered by whole exome sequencing (WES), is transforming reproductive health decisions.

Explore the impact of CGT with our expert panel.

Don't miss out!

🔬 Exciting News Alert! Join us for our upcoming webinar hosted by Igenomix! 🔬

📅 Date: May 16th
🕒 Time: 11am PST / 2pm EST
🔗 Registration: https://attendee.gotowebinar.com/register/726602802566427740

Empowering informed decisions in genetic health is at the core of what we do at Igenomix. That's why we're thrilled to extend an exclusive invitation to you for our upcoming webinar, "Closing the Gaps in Carrier Screening."

Carrier Genetic Testing (CGT) is revolutionizing genetic screening, offering unparalleled insights into potential risks that could affect future generations. Join us as we explore how CGT, powered by whole exome sequencing (WES), is transforming reproductive health decisions.

Explore the impact of CGT with our expert panel.

Don't miss out!

Vitrolife Group acquires eFertility, an innovative system and software company transforming IVF clinic management with cutting edge solutions.

We are delighted to announce that today, the Vitrolife Group successfully completed the acquisition of eFertility. This acquisition is a key element of the Vitrolife Group’s strategy to bring increased standardisation and digitalisation to IVF clinics around the world.

“The acquisition of eFertility represents a significant step in the Vitrolife Group’s strategy to transform and digitalise the IVF patient journey. By incorporating eFertility’s technologies into our platform, we are making critical advancements towards the development of a seamlessly integrated and more efficient clinic workflow." said Bronwyn Brophy, CEO of Vitrolife Group.

Read the full press release here: https://www.vitrolifegroup.com/en/investor-relations/press-releases?page=/en/press/vitrolife-ab-publ-acquires-efertility

Vitrolife and Igenomix, both part of , are excited to meet you at the 21st PGDIS Conference in Kuala Lumpur, Malaysia, from May 6th to 8th.

If you're in attendance, we welcome you to stop by Booth B1 to explore our high-quality solutions tailored to enhance your lab or clinic capabilities.

See you at Booth B1!

📣 We're thrilled to announce that will be participating in the 21st PGDIS Conference, that will be held in Kuala Lumpur, Malaysia from May 6th to 8th, 2024 📅

Join us at booth B1 to explore our latest offerings tailored to meet the specific requirements of your lab or clinic. Don't miss this chance to engage with us and discover how we can enhance your practice.

Looking forward to seeing you in Kuala Lumpur!

Happy DNA Day! 🧬

Today, we commemorate the discovery of the DNA double helix structure.

Igenomix, specializing in reproductive genetics, utilizes DNA-based services to help individuals and couples realize their dreams of starting a family. Let's acknowledge DNA's vital role in advancing science and enhancing human health.

Join us in celebrating Canadian Fertility Awareness Week and using our voices to make a difference! It's a time to raise awareness, share stories, and support those on their fertility journeys. 💚

What does mean to me? It means empowerment, advocacy, and fostering a community where no one feels alone. Let's come together and make a positive impact during !

This week is National Infertility Awareness Week🧡

The movement was created by RESOLVE: The National Infertility Association to empower those facing infertility and to change the conversation surrounding it through education.

1 in 6 couples suffer from infertility and at Vitrolife Group, we have a vision with a purpose: to enable people to fulfill the dream of having a healthy baby. Our passion and commitment to making a real difference in the world of reproduction have never been more dedicated, and our thoughts are constantly with those who have faced, or are facing, infertility🧡

We are excited to announce that our colleague, Dr. Carmen Rubio, will be participating in the upcoming ESHRE Campus 2024 that will be held in Prague, Czech Republic.

Session 5: Invasive, minimally invasive and non-invasive embryo genetic testing

11:30 - 11:50 (CET) Tips and tricks to improve minimally and non-invasive strategies for embryo assessment.

Presented by: Carmen Rubio LLuesa, Spain

Register here: https://lnkd.in/dCruuurb

-invasivePGTA

We are excited to announce that our colleague, Dr. Carmen Rubio, will be participating in the upcoming ESHRE Campus 2024 that will be held in Prague, Czech Republic.

Session 5: Invasive, minimally invasive and non-invasive embryo genetic testing

11:30 - 11:50 (CET) Tips and tricks to improve minimally and non-invasive strategies for embryo assessment.

Presented by: Carmen Rubio LLuesa, Spain

Register here: https://www.eshre.eu/Education/Calendar-Campus-events/When-embryology-meets-genetics/Registration

-invasivePGTA

We are pleased to announce the release of the Vitrolife Group Annual and Sustainability Report for 2023.

Take a look inside to explore our recent achievements and the launch of our new corporate strategy. As we embark on this ambitious journey, our mission is clear: to be the leading global partner in reproductive health, striving for better treatment outcomes for patients.

https://www.vitrolifegroup.com/en/investor-relations/press-releases?page=/en/press/vitrolife-group-annual-and-sustainability-report-2023

Missed out on our enlightening webinar, 'Proper Protocol Compliance to Optimize Your Clinic's ERA Outcomes - Volume 1: The Importance of Endogenous Progesterone Control' by Dr. Tiffany Stankewicz, Endometrio Product Director at Igenomix?

Don't worry! You can catch up by watching the recording at the link below. Stay informed and enhance your clinic's practices!

Link: https://youtu.be/LnwhehvGoIc?si=G20uCD4PrpmRHC9r

Igenomix is proud to be a sponsor of CFS 2024. Join us on Saturday, April 20th, at the International Centre Toronto. Don't miss our Scientific Advisor, Alissa Magwood as she presents an oral presentation, "Moving Forward: Insights on New Advanced Testing after Pregnancy Loss."

Did you miss out on the webinar about "Quality all the way - It's not what you do, it's the way that you do it!"?

Erik Strait, MEA Lab Manager at Vitrolife Group, educates us on the mouse embryo assay (MEA), the most valuable tool Vitrolife has to ensure safe and consistent products. It makes it possible for clinics to create a safe and optimal environment for embryo development and ultimately ensure successful results for patients.

Moderator:
Jaco Terblanche, Vitrolife Academy Director, Vitrolife Group

Presenter:
Erik Strait, Lab Manager MEA, Vitrolife Group

Watch the recording here: https://learn.vitrolife.com/thank-you-webinar-quality-all-the-way

Qualityalltheway

🌟 Join us for an engaging webinar "Proper protocol compliance to optimize your clinic’s ERA outcomes - Volume 1: The importance of endogenous progesterone control" by Dr. Tiffany Stankewicz, Endometrio Product Director at Igenomix.

📅 Save the Date: Saturday, April 6th, 2024
⏰ Time: 6:00AM PST / 9:00AM EST
📌 Register here: https://igenomix.tfaforms.net/99?CampaignID=7016900000207fr

We look forward to having you with us.

👁 Discover the complete POC portfolio, making us the only company to provide all available market options for deciding the most beneficial test for your patient post-pregnancy loss 🧬

Learn more about the complete POC portfolio here: https://www.igenomix.eu/poc-portfolio/

March 21st is World Down Syndrome Day, a moment to highlight Down’s Syndrome, a chromosomal disorder characterized by the presence of an extra chromosome 21. This condition brings significant medical challenges and developmental hurdles for those affected.

During pregnancy, the NACE test can indicate the risk of this condition. Early diagnosis makes it possible to treat a baby with this syndrome at an early stage and thus improves its quality of life.

On March 18th, we observe Trisomy 18 Awareness Day, a time to shine a light on Edwards syndrome, a chromosomal disorder characterized by the presence of an extra chromosome 18. This condition brings significant medical challenges and developmental hurdles for those affected.

During pregnancy, the NACE test can indicate the risk of this condition. Early diagnosis makes it possible to treat a baby with this syndrome at an early stage and thus improves its quality of life.

Discover the incredible benefits of Igenomix genetic testing! 🧬✨

🔍 Early detection of genetic risks: ensure early awareness of potential genetic challenges, enabling preparation and appropriate action.

💡 Informed decision-making: our tests provide valuable information to make informed decisions about health and the future.

🌟 Personalization of treatment: every patient is unique, and so are their needs. Personalized treatment based on accurate genetic information.

🤝 Specialized genetic counselling: our team of experts is here to guide the patient every step of the way, offering support and understanding on their genetic journey.

⏰ Reduction of the time to pregnancy: with detailed information, we optimize the path to pregnancy, reducing the time to have a healthy baby at home.

💥Join our global webinar!

Quality all the way - It's not what you do, it's the way that you do it!

Our quality control program has been a leading industry standard for more than 20 years and remains a cornerstone of our business. All Vitrolife products are subjected to a comprehensive quality control designed for human embryos. Our customers must know that they can rely on our products, and this is guaranteed through extensive testing and high lot-to-lot consistency.

In this webinar Erik Strait, MEA Lab Manager at Vitrolife Group, will educate us on the Mouse Embryo Assay (MEA), the most valuable tool Vitrolife has to ensure safe and consistent products. It makes it possible for clinics to create a safe and optimal environment for embryo development and ultimately ensure successful results for patients.

Moderator

@ Jaco Terblanche, Vitrolife Academy Director, Vitrolife Group

Presenter

@ Erik Strait, Lab Manager MEA, Vitrolife Group

Date: 26th of March

Time: 9 am MDT, 4 pm CET

Register now: learn.vitrolife.com/webinar-quality-all-the-way

👩 This International Women's Day, Vitrolife Group is proud to share that we have nearly achieved gender parity in our management positions, with women occupying almost half of these roles with a 48% representation. We take immense pride in their achievements and are committed to supporting their leadership journey. Our goal is clear: to further foster a culture where female leadership flourishes, ensuring an inclusive future for our company.

niPOC:

An advanced non-invasive blood test that determines whether a pregnancy loss was caused by a chromosome abnormality. With just a blood sample, it analyses 24 chromosomes to determine the reason behind the miscarriage. This test completes the POC family portfolio, making us the only company to provide all available market options for deciding the most beneficial test for your patient post-pregnancy loss.

Discover the complete portfolio here: www.igenomix.ca

Today is Rare Disease Day.

🧬 There are 300 million people worldwide living with a rare disease.
🧬 There are over 6,000 identified rare diseases.
🧬 72% of all rare diseases are genetic.
🧬 70% of rare genetic diseases start in childhood.
🧬 5% of the world's population are currently affected by rare diseases.

Researchers play a critical role in advancing diagnosis and treatment for people with rare diseases. Their work leads to improved understanding, earlier detection, and the development of effective therapies.

Celebrating Love:

Vitrolife Group stands for enabling dreams – the dream of having a healthy baby. Every two minutes, our products help bring a healthy baby into the world.

Together as a team, we're honoured to be a part of this wonderful journey of love!

We wish you all a lovely Valentines Day! 💙